Photosensitive antibody-phuorophore conjugates

An antibody, -IR700 technology, applied in the field of photosensitive antibody-fluorophore conjugates, which can solve problems such as side effects

Inactive Publication Date: 2014-05-07
UNITED STATES OF AMERICA
View PDF7 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the dose-limiting toxicity is ultimately related to the biodistribution and catabolism of the antibody conjugate
[0006] Conventional photodynamic therapy (PDT), which combines photosensitizers with the physical energy of non-ionizing light to kill cells, is less commonly used as a cancer therapy because current non-targeted photosensitizers are also absorbed by normal tissues, causing Serious side effects, although the excitation light itself is harmless in the near-infrared (NIR) range (Figure 9)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Photosensitive antibody-phuorophore conjugates
  • Photosensitive antibody-phuorophore conjugates
  • Photosensitive antibody-phuorophore conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0190] Synthesis of IRDye700-conjugated trastuzumab (anti-Her2)

[0191] This example describes the method used to conjugate the monoclonal antibody trastuzumab to IRye700DX NHS Ester. Those skilled in the art will recognize that any antibody, such as any monoclonal antibody specific for a target cell surface protein, can be conjugated to the IRDye700DX NHS Ester using similar methods.

[0192] The humanized HER2 antibody trastuzumab (Tra; Genentech, San Francisco, CA) (1 mg, 6.8 nmol) was mixed with IRDye700DX NHS Ester (IR700; LI-COR Bioscience, Lincoln, NE) (66.8 μg, 34.2 nmol, in 5mmol / L in DMSO) in 0.1mol / L Na 2 HPO 4 (pH 8.5) for 30-120 minutes at room temperature. Trastuzumab is a recombinant humanized monoclonal antibody (mAb) directed against the extracellular domain of the human epidermal growth factor receptor (EGFR) 2 (HER2) tyrosine kinase receptor. The mixture was purified with a Sephadex G50 column (PD-10; GE Healthcare, Piscataway, NJ). Protein concentrati...

Embodiment 2

[0196] Selectively kills HER2+ cells

[0197] This example is described to demonstrate that the trastuzumab-IR700 compound described in Example 1 (referred to herein as Tra-IR700) can be used to selectively kill cells expressing HER2 (HER2+) while being negative for HER2 (HER2-) Cellular approach with minimal side effects.

[0198] NIH3T3 (3T3 / HER2+) cells transfected with HER2 gene were used for targeted photodynamic therapy (PDT). Balb / 3T3 cells expressing DsRed fluorescent protein but not expressing HER2 (Balb / 3T3 / DsRed) were used as a control. Culture cells in tissue culture dishes in RPMI1640 supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin in a humidified incubator at 37°C in an atmosphere of 95% air and 5% carbon dioxide .

[0199] Fluorescence microscopy was performed with a BX51 or IX81 microscope (Olympus America, Melville, NY). Filters were set to detect IR700 and consisted of a 590-650 nm excitation filter and a 665-740 nm bandpass emissi...

Embodiment 3

[0204] Determining the radiation dose

[0205] To determine phototoxicity in response to different light exposure doses, the LIVE / Fixable Green Dead Cell Staining Kit was used to measure PDT-treated 3T3 / HER2+ cells by flow cytometry. A LIVE / DEAD assay that detects cells with damaged membranes was performed within one hour of the treatment. As shown in Figure 1d, cell death in response to Tra-IR700-mediated PDT was light-dose-dependent after 1 h of PIT. Cells showed no significant phototoxicity in the absence of PIT or Tra-IR700.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm<-2>. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

Description

[0001] Cross References to Related Applications [0002] This application is a continuation-in-part of U.S. Application No. 13 / 180,111, filed July 11, 2011, which claims priority to U.S. Provisional Application No. 61 / 363,079, filed July 9, 2010, both incorporated by reference way into this article. technical field [0003] The present application relates to antibody-IR700 conjugates and methods of using antibody-IR700 conjugates to kill cells specifically bound to said antibodies after irradiation with infrared (NIR) light. Also provided are devices incorporating NIR light emitting diodes (LEDs) that can also be used with the conjugates and methods of the present disclosure. Background technique [0004] In 2007, about 13% of all human deaths were caused by cancer. Although there are some therapies against cancer, there remains a need for therapies that effectively kill tumor cells while sparing non-cancerous cells. [0005] To minimize the side effects of conventional c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K41/00A61K49/00A41D27/08
CPCA61K41/0071A61K49/0032A61K49/0058C07K16/2863C07K16/3069C07K16/32C07K2317/24C07K2317/73A41D13/0002A41D2400/32A44C15/00A61K2039/505A61K47/6803A61K47/6869C07K16/30
Inventor 小林久隆P·库伊克M·博纳多
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap